Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Diabetes/metabolism Research and Reviews
Matthew C RiddleDavid Maggs

Abstract

In two placebo-controlled 30-week trials, treatment with exenatide reduced HbA(1c) and body weight in patients with type 2 diabetes in the context of sulphonylurea (SU) or SU plus metformin (MET) as background treatment. This analysis examines the effects of 82 weeks of exenatide treatment for participants in these earlier 30-week trials. Data were pooled from the two pivotal trials of exenatide added to SU or SU plus MET. Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies. This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]). Reduction in HbA(1c) from baseline to week 30 (-0.8 +/- 0.1% and -1.0 +/- 0.1% for 5 microg b.i.d. and 10 microg b.i.d., respectively [mean +/- SE]) was sustained up to week 82 (-1.0 +/- 0.1%). Of 207 patients with baseline HbA(1c) > 7%, 44% achieved HbA(1c) < or = 7% at week 82. Reduction of body weight from baseline to week 30 (-1.4 +/- 0.3 kg and -2.1 +/- 0.3 kg f...Continue Reading

References

Jun 1, 1992·Diabetes Care·L C Groop
Jan 1, 1982·European Journal of Clinical Pharmacology·E Wåhlin-BollB Scherstén
Nov 20, 1998·Lancet·C V Dang, L B Gardner
Jun 16, 1999·Diabetes Research and Clinical Practice·T MarburyH Lebovitz
Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo
Sep 2, 1999·Lancet·J Chard
Sep 2, 1999·Lancet·R Ruffmann
Apr 24, 2001·Diabetes Care·H Yki-Järvinen
Jun 19, 2001·American Journal of Physiology. Endocrinology and Metabolism·C M EdwardsS R Bloom
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
May 6, 2005·Treatments in Endocrinology·Jonathan Q Purnell, Christian Weyer

❮ Previous
Next ❯

Citations

Feb 22, 2011·Reviews in Endocrine & Metabolic Disorders·Jenny Tong, Darleen A Sandoval
Jan 5, 2008·Current Diabetes Reports·Jennifer B Green, Mark N Feinglos
Oct 2, 2009·Current Diabetes Reports·Catherine M Champagne
Sep 1, 2007·Hepatology International·David van der Poorten, Jacob George
Nov 30, 2010·Journal of the American Dietetic Association·Marion J FranzErica Gradwell
Apr 14, 2009·International Journal of Obesity : Journal of the International Association for the Study of Obesity·H J Grill, M R Hayes
Jul 27, 2007·The New England Journal of Medicine·Robert J Heine, Robert Brodows
Aug 1, 2012·Diabetes Technology & Therapeutics·Krystal L EdwardsBrian K Irons
Apr 26, 2008·Diabetes, Obesity & Metabolism·Kasper AaboeJens Juul Holst
Jun 28, 2012·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·David P BradleyDale A Schoeller
May 10, 2007·The Review of Diabetic Studies : RDS·Baptist Gallwitz
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Peggy Soule Odegard, Anthony Desantis
Mar 20, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Roy D Bloom, Michael F Crutchlow
Jun 2, 2012·World Journal of Gastroenterology : WJG·Meir MizrahiYaron Ilan
Jan 26, 2008·Current Medical Research and Opinion·Leonard C GlassRichard M Bergenstal
Jun 5, 2012·Pharmacology & Therapeutics·Young Min ChoTimothy J Kieffer
Jun 20, 2012·Neuropharmacology·Steven P Vickers, Peter G Clifton
Feb 2, 2011·Pediatric Clinics of North America·Donald E GreydanusCynthia Feucht
Feb 16, 2010·Nutrition·David P BradleyDale A Schoeller
Nov 26, 2009·Pharmacology & Therapeutics·Abd A TahraniAnthony H Barnett
Sep 2, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·S L NorrisB K S Chan
Sep 14, 2007·International Journal of Clinical Practice·R P Vincent, C W le Roux
Mar 16, 2011·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·S S TorekovJ J Holst
Dec 17, 2009·British Journal of Clinical Pharmacology·Benjamin C T FieldStephen R Bloom
Oct 13, 2007·Expert Opinion on Pharmacotherapy·A Barnett
Jun 15, 2015·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Chao-Lin LiJia-Jun Zhao
Apr 15, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Yehuda HandelsmanFarhad Zangeneh
Jan 8, 2017·Annual Review of Pharmacology and Toxicology·Georgios ValsamakisGeorge Mastorakos
Sep 9, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·John H B Scarpello, Harry C S Howlett
Feb 14, 2015·Therapeutic Advances in Endocrinology and Metabolism·Kira B Harris, Delilah J McCarty
Jul 24, 2008·The Diabetes Educator·Catherine L Martin
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Deepson S ShyangdanAlisa Snaith
Nov 1, 2008·Expert Review of Endocrinology & Metabolism·Abd A TahraniAnthony H Barnett

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.